Current paradigms in epigenetic anticancer therapeutics and future challenges-Reference-Cited by-同舟云学术

Current paradigms in epigenetic anticancer therapeutics and future challenges

Published:2021-03 Issue: Volume: Page:
ISSN:1044-579X
Container-title:Seminars in Cancer Biology
language:en
Short-container-title:Seminars in Cancer Biology

Author:

Singh Manoj,Kumar Vikas^ORCID,Sehrawat Nirmala^ORCID,Yadav Mukesh^ORCID,Chaudhary Mayank^ORCID,Upadhyay Sushil K.,Kumar Sunil,Sharma Varruchi,Kumar Sandeep,Dilbaghi Neeraj,Sharma Anil K.^ORCID

Publisher

Elsevier BV

Subject

Cancer Research

Reference299 articles.

1. Deaths: leading causes for 2017;Heron,2019

2. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance;Easwaran;Mol. Cell,2014

3. Oncogenes and tumor suppressor genes: comparative genomics and network perspectives;Zhu;BMC Genomics,2015

4. X chromosome dosage influences DNA methylation dynamics during reprogramming to mouse iPSCs;Pasque;Stem Cell Reports,2018

5. Epigenetic determinants of cancer;Baylin;Cold Spring Harb. Perspect. Biol.,2016

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preliminary study on the mechanism of SAHA in the treatment of refractory epilepsy induced by GABRG2(F343L) mutation;Biochemical Pharmacology;2024-09

2. DNMT3A loss drives a HIF-1-dependent synthetic lethality to HDAC6 inhibition in non-small cell lung cancer;Acta Pharmaceutica Sinica B;2024-09

3. Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy;Discover Oncology;2024-08-11

4. Inhibition of HDAC2 sensitises antitumour therapy by promoting NLRP3/GSDMD‐mediated pyroptosis in colorectal cancer;Clinical and Translational Medicine;2024-05-28

5. Current trends in clinical trials and the development of small molecule epigenetic inhibitors as cancer therapeutics;Epigenomics;2024-04-19